ClinicalTrials.gg
TerminatedNCT04843345Updated Nov 9, 2026

Sjogren's Lung Study

An observational study in Sjogren's Syndrome, Interstitial Lung Disease and Primary Pulmonary Lymphoma (Disorder), sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Stanford University · Observational

How we know

Why this study was terminated
Change in research staffing
Updated Nov 9, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
51
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
27th of 35
51 · median 220
Started
2021
with 9 others
Observational
35 of 111
9 open now
Registered
80th of 111
by date

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 27th largest by enrollment of the 35 observational ones that give a count, is one of 10 that started in 2021, is one of 35 observational ones, and was the 80th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

Lung involvement in Sjögren's syndrome is common and causes reduced quality of life and increased mortality. Sjögren's syndrome-related lung diseases (SS-RLD) are classified and treated as the primary lung diseases they resemble. Whether this approach is optimal has not been evaluated thoroughly. A critical gap in knowledge is knowing whether SS-RLDs have a unique clinical course and response to therapy. Given the underlying immune system dysfunction in Sjögren's syndrome, the investigators hypothesize that patients with SS-RLD will be more likely to respond to immunosuppressive therapy than patients with the matching primary lung disease. To address this hypothesis, the investigators will prospectively screen for Sjogren's syndrome in patients presenting to pulmonary clinics and compare the clinical course and response to therapy in Sjogren's syndrome positive and negative patients.

Read the detailed description

Sjögren's syndrome is an autoimmune disease affecting at least 1% of adults characterized by hyperactive lymphocytes that damage exocrine glands leading to dry eyes and dry mouth. Although less well recognized, lung involvement in Sjögren's syndrome is common and causes reduced health-related quality of life and increased mortality. Sjögren's syndrome-related lung diseases are classified and treated as the primary lung diseases they resemble. Whether this approach is optimal has not been evaluated thoroughly.

Despite the potentially life-threatening consequence of Sjögren's syndrome-related lung disease, general medical education still promotes the false idea that Sjögren's syndrome is a nuisance disease. This leads many clinicians to overlook Sjögren's syndrome as a possible cause for respiratory symptoms. Even when Sjögren's syndrome is identified, there is no standard for attribution of the lung disease and little data on how to best treat it.

Only one study has compared interstitial lung disease patients with and without Sjögren's syndrome. Although it was a small retrospective study, it found that patients with usual interstitial pneumonia and Sjögren's syndrome were more likely to achieve stable lung function with immunosuppressive therapy as compared to the idiopathic cohort. This is striking as usual interstitial pneumonia is generally thought to not be responsive to immunosuppressive therapy.

A critical gap in knowledge is knowing whether Sjögren's syndrome-related lung diseases have a unique clinical course and response to therapy. Given the underlying immune system dysfunction in Sjögren's syndrome, the investigators hypothesize that patients with Sjögren's syndrome-related lung disease will be more likely to respond to immunosuppressive therapy than patients with the matching primary lung disease.

03

Conditions studied

  • Sjogren's Syndrome
  • Interstitial Lung Disease
  • Primary Pulmonary Lymphoma (Disorder)
  • Chronic Bronchiolitis
  • Bronchiectasis
  • Lung Diseases
  • Cystic Lung Disease
  • Lymphocytic Interst. Pneumonitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The investigators aim to capture a wide range of adult patients with lung disease to better understand the contribution of Sjogren's syndrome to lung disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group 1: Interstitial Lung Disease and Other Parenchymal Lung Diseases

  • Known or suspected interstitial lung disease regardless of radiographic pattern
  • Interstitial lung disease due to alternative etiology
  • Sarcoidosis
  • Organizing pneumonia
  • pneumonitis absent known or suspected trigger
  • Primary pulmonary lymphoma
  • Other idiopathic pulmonary conditions at discretion of study team

Group 2: Airway Symptoms

  • Chronic cough despite treatment trials with albuterol, proton-pump inhibitors and anti-histamine and intranasal
  • Persistent bronchial hyperreactivity (defined as positive response to methacholine challenge on spirometry or subjective worsening after exposure to airway irritants such as tobacco, pollution, etc) or persistent asthma symptoms despite trial of inhaled corticosteroid and long acting bronchodilator
  • Unexplained persistent bronchial wall thickening on CT imaging
  • Recurrent or chronic bronchiolitis (including but not limited to chronic bronchiolitis, obliterative bronchiolitis, lymphocytic bronchiolitis, constrictive bronchiolitis associated with bronchiolar destruction, and panbronchiolitis)
  • Bronchiectasis
  • Lymphocytic alveolitis on bronchoalveolar lavage absent hypersensitivity pneumonitis with known trigger or
  • Recurrent bacterial pneumonia (greater than 2 episodes in 1 year, confirmed by focal consolidative opacity on chest imaging and requiring antibiotic therapy)

Group 3: Other

•Select patients outside the protocol testing schema who have one of the above lung diseases and are found to have Sjogren's syndrome through the course of their normal clinical care will be invited to participate in the data collection portion of the study for analyzing longitudinal outcomes.

Exclusion criteria

Exclusion Criteria:

  • Patients with interstitial lung disease due to a known or suspected trigger such as drug-induced (including but not limited to nitrofurantoin, amiodarone, methotrexate and other chemotherapies), inorganic dust exposure (including but not limited to asbestos, silica, hard metals, coal dust) or organic exposure (including but not limited to birds, hay, mold).
  • Patients who have taken a muscarinic antagonist or agonists within 7 days of planned testing
  • Patients who are unable to consent for themselves
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
51 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Reduced Salivary Flow Patients

    Patients with lung disease matching inclusion criteria who screen positive for reduced salivary flow

  • Normal Salivary Flow Patients

    Patients with lung disease matching inclusion criteria who screen negative for reduced salivary flow

06

What researchers measure

Primary outcomes

  1. Change in pulmonary function over time

    Based on underlying lung disease, standard measures of lung function (FEV1 vs FVC) will be followed

    Time frame: Change from first test after enrollment to final test across 5-year monitoring period

Secondary outcomes

  1. Annual rate of hospitalizations from respiratory cause

    Time frame: Over 5-year monitoring period

  2. Percent of participants who die from respiratory cause

    Time frame: Over 5-year monitoring period

07

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2021 to primary completion in Jan 2022, 9 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Apr 2028 → Jan 2022 and completion Apr 2030 → Jan 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 13, 2021
StartActual
Apr 1, 2021
Primary completionActual
Jan 18, 2022was Apr 2028
CompletionActual
Jan 18, 2022was Apr 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated Change in research staffing
changed Nov 9, 2026
Primary completion
Apr 1, 2028→Jan 18, 2022 (actual)
Nov 9, 2026
Study completion
Apr 1, 2030→Jan 18, 2022 (actual)
Nov 9, 2026
Enrollment
500 (estimated)→51 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Suspended→Terminated
    Why stopped Change in research staffing
    Primary completion Apr 1, 2028→Jan 18, 2022 (now actual)
    Study completion Apr 1, 2030→Jan 18, 2022 (now actual)
    Enrollment 500 (estimated)→51 (actual)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04843345
Responsible party
Sponsor
First posted
Apr 13, 2021
Start date
Apr 1, 2021
Primary completion
Jan 18, 2022
Completion
Jan 18, 2022
Last update
Nov 9, 2026

Study contacts

Jason H Melehani, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion